Discover how intellectual property rights protect exclusive pharmaceutical use and brand names in biotechnology, influencing innovation and market dynamics.

A US court has upheld AstraZeneca’s patents on its respiratory drug Symbicort, blocking cheaper competition for the ageing blockbuster. The US District Court for the Northern District of West Virginia ...

Clinical Study Report Synopsis [D5890L00008]: A comparison of the efficacy of Symbicort SMART (Symbicort)Turbuhaler 160/4.5 μg 1 inhalation b.i.d. plus as-needed) and conventional best standard ...

Symbicort is an inhaler used for long-term control of asthma and COPD, but it is not a rescue inhaler. Before using Symbicort, tell your healthcare provider if you have health conditions like adrenal ...

The price you pay for Symbicort may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. You may be able to lower your long-term costs by getting a ...

Between December 2020 and July 2022, we conducted a 52-week, open-label, single-arm trial of 100 adults aged 18–75 with asthma, with 25 patients each on Global Initiative for Asthma 2018 treatment ...

President Joe Biden’s career-defining victories over Big Pharma — reforming Medicare to lower prices and capping inhaler costs for millions of Americans with lung disease — are facing an unlikely ...

Some COPD inhalers should not be used together because they can cause dangerous side effects. Using inhalers from the same drug class can increase the risk of overdose and side effects. Always check ...

Asthma affects 2 out of 10 people in Scotland and this chronic, variable, inflammatory disease is characterised by asthma attacks and symptoms including breathlessness and wheezing. [7] 'Mild' asthma ...